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Abstract
Pre-mRNA splicing by the spliceosome is an essential step in the maturation of nearly all human mRNAs. Mutations in six
spliceosomal proteins, PRPF3, PRPF4, PRPF6, PRPF8, PRPF31 and SNRNP200, cause retinitis pigmentosa (RP), a disease
characterized by progressive photoreceptor degeneration. All splicing factors linked to RP are constituents of the U4/U6.U5
tri-snRNP subunit of the spliceosome, suggesting that the compromised function of this particle may lead to RP. Here, we
report the identification of the p.R192H variant of the tri-snRNP factor PRPF4 in a patient with RP. The mutation affects a
highly conserved arginine residue that is crucial for PRPF4 function. Introduction of a corresponding mutation into the
zebrafish homolog of PRPF4 resulted in a complete loss of function in vivo. A series of biochemical experiments suggested
that p.R192H disrupts the binding interface between PRPF4 and its interactor PRPF3. This interferes with the ability of PRPF4
to integrate into the tri-snRNP, as shown in a human cell line and in zebrafish embryos. These data suggest that the p.R192H
variant of PRPF4 represents a functional null allele. The resulting haploinsufficiency of PRPF4 compromises the function of
the tri-snRNP, reinforcing the notion that this spliceosomal particle is of crucial importance in the physiology of the retina.
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Introduction
Mutations that interfere with splicing are a frequent cause of
human disease [1,2]. The majority of these mutations affect pre-
mRNA splice sites or regulatory elements in cis [3]. However, also
mutations that interfere with the trans-acting machinery that
catalyzes the splicing reaction – the spliceosome – can lead to
disease [4–7]. Surprisingly, despite the essential role of pre-mRNA
splicing for gene expression on a transcriptome-wide scale,
mutations in general splicing factors are often associated with
specific phenotypes that are restricted to a particular tissue or even
cell type [2]. A prime example for such a tissue specificity paradox
is the hereditary eye disease retinitis pigmentosa (RP), which is
characterized by a selective loss of photoreceptor cells in the
retina. As a consequence, patients suffer from a severe visual
handicap [8]. Although this phenotype is highly selective and
affects primarily rod photoreceptors, a substantial fraction of RP-
cases have been linked to mutations in the general splicing factors
PRPF3, PRPF4, PRPF6, PRPF8, PRPF31 and SNRNP200 [9–
14].
The aforementioned proteins are part of the spliceosome, a
highly dynamic molecular machine that consists of five small
nuclear ribonucleoprotein particles (snRNPs; termed according to
their RNA content U1, U2, U4/U6 and U5) and a large set of
non-snRNP factors [15]. It is formed in a stepwise manner on the
cis-acting sequence elements of introns, including the branch point
and the 59 and 39 splice sites, which define the boundaries to
exons. In a first step, U1 and U2 snRNPs bind to the 59-splice site
and the branch point, respectively. The resulting pre-spliceosomal
complex then recruits U4/U6 and U5 snRNPs, which form prior
to their integration into the spliceosome the so-called U4/U6.U5-
tri-snRNP. Structural rearrangements then lead to the release of
U1 and U4 snRNPs, and the formation of the catalytically active
spliceosome. After splicing, the spliceosome is disassembled and its
individual subunits are recycled so that they can re-assemble on
another intron. While U1 and U2 snRNPs are recycled as ‘‘mono-
snRNPs’’, the tri-snRNP is rebuilt by the joining of the snRNPs
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U4 and U6, which generates a U4/U6 di-snRNP that is
subsequently bound by the U5 snRNP [16].
Intriguingly, every splicing factor linked to RP thus far is a
component of the U4/U6.U5 tri-snRNP. The tri-snRNP is
essential for the formation of the active center of the spliceosome,
participates in splice site selection and has been recently proposed
to recruit the nuclear RNA surveillance machinery to mRNAs
[17–19]. It has been hypothesized that defects in RP-linked
splicing factors affect gene expression in a manner to which the
retina is uniquely sensitive [20,21]. In line with this hypothesis, we
have recently shown in a zebrafish model for RP that the
deficiency of PRPF31 predominantly affects the expression of
retina-specific transcripts [22]. Many of the affected transcripts
were also associated with retinal disease, thereby providing a direct
link between defects in general splicing factors and a retinal
phenotype. Of note, the knockdown of another tri-snRNP protein,
PRPF4, resulted in a photoreceptor-specific phenotype that was
indistinguishable from that of the PRPF31 model [22]. Therefore,
we reasoned that PRPF4 could be similarly involved in the
pathogenesis of RP and screened patients for mutations in the
PRPF4 gene.
Here, we characterize the molecular and physiological effects of
a missense mutation (p.R192H) in the tri-snRNP factor, PRPF4,
which was identified in a sporadic RP patient. Several lines of
evidence suggest that this variant represents a loss-of-function
allele. First, a corresponding mutation in the zebrafish PRPF4
homolog rendered it physiologically inactive. Second, binding of
PRPF4 to its interactor PRPF3 was abrogated by the p.R192H
amino acid exchange. Third, variant PRPF4 failed to integrate
into the tri-snRNP in human cell lines and zebrafish embryos.
Together, these findings indicate that PRPF4 haploinsufficiency
may contribute to RP. Furthermore, they underline the role of tri-
snRNP splicing factors as mutational hotspots in RP and
demonstrate the feasibility of a direct analysis of these candidate
genes in RP patients.
Results
Identification of a loss-of-function variant of the splicing
factor PRPF4 in a patient with RP
We screened DNA samples from 85 patients with sporadic or
autosomal dominant RP (adRP) for mutations in PRPF4. This
revealed a heterozygous non-synonymous nucleotide exchange,
c.575G.A, in the sporadic female patient RP-106 (Fig. 1A). At
the age of 39 years, RP-106 had stopped driving because of night
blindness. Constriction of the visual field was noted at the age of
approximately 45 years. With 55 years of age, early cataracts were
found. Funduscopy showed pale papillae, narrowing of retinal
vessels, and bone spicule-like pigmentation in the periphery. The
scotopic electroretinogram (ERG) was extinguished, the photopic
ERG was almost extinguished. RP-106 has two daughters (III:2,
54 years, and III:4, 52 years). III:4 was found to carry the
c.575G.A variant. III:2 and III:4 underwent detailed ophthal-
mological investigation including assessment of visual acuity,
funduscopy, perimetry, dark adaptation and ERG and did not
show any signs of retinal degeneration. As shown in a recent study
by Chen et al. [10], the onset of PRPF4-associated RP is variable
(between 15 and 27 years of age). Both inter- and intrafamilial
clinical variability are common in RP. The reported onset of visual
complaints (20 years of age) in our patient corresponds to the
range reported by Chen et al [10].
Although c.575G.A was annotated as a single nucleotide
polymorphism (SNP) in the dbSNP database (rs41296057; http://
www.ncbi.nlm.nih.gov/SNP/), this entry did not contain infor-
mation about allele frequency or validation status. Furthermore,
c.575G.A was not present in 13,006 control chromosomes
deposited in the Exome Variant Server (http://evs.gs.washington.
edu/EVS/) and 2,188 chromosomes deposited in the 1000ge-
nomes database (http://www.1000genomes.org/). These data
suggested that c.575G.A is a very rare PRPF4 variant. The
predicted amino acid exchange affects a highly conserved arginine
residue at position 192 (p.R192H) and was predicted by the
PROVEAN, PolyPhen-2 and SIFT algorithms to have a
deleterious effect [23–25]. Hence, we set out to analyze the
impact of the p.R192H variant on PRPF4 protein function.
First, we wanted to investigate whether the mutant allele acts in
a dominant negative manner. For this, zebrafish embryos were
injected with mRNAs transcribed in vitro encoding for a fusion
protein of an N-terminal hemagglutinin epitope (HA-tag) and
zebrafish Prpf4, either in wildtype form or with an amino acid
exchange that corresponds to p.R192H. The HA-tag allowed for
the simultaneous and semi-quantitative detection of exogenous
and endogenous protein by Western blotting using a Prpf4-specific
antibody. This revealed an overexpression of exogenous HA-prpf4
(wildtype and mutant) in fish that were injected with the
corresponding mRNAs (Figure 2A, upper panel). Yet, neither of
the proteins interfered with normal embryonic development (Fig.2
A, lower panel), suggesting that p.R192H does not have a strong
dominant negative effect.
Next, we addressed the possibility that p.R192H results in a loss
of function. For this, we included the p.R192H mutant in our
rescue analysis of severe Prpf4 deficiency [22]. In this assay,
zebrafish embryos were injected with a dose of antisense
morpholino that strongly reduces Prpf4 expression (Fig. 2B,
compare lanes 1 and 2 with lanes 3 and 4) and leads to an
embryonic lethal phenotype (Fig. 2, compare C and D). Although
the co-injection of in vitro transcribed, morpholino-insensitive
Figure 1. RP family described herein. II:2, index patient and
heterozygous carrier of the PRPF4 variant p.R192H. Arrows, individuals
who were available for genetic and clinical characterization. Circles,
female individuals; Squares, male individuals. Filled symbols indicate
affected persons. White symbols, unaffected persons by detailed
ophthalmological investigation (III:2, III:4) or medical history. III:4,
healthy carrier of the PRPF4 variant. Crossed symbols, deceased
persons. Age at the time of examination is given below the pedigree
symbols.
doi:10.1371/journal.pone.0111754.g001
PRPF4 Loss of Function in RP
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mRNAs encoding HA-Prpf4 in either wildtype or mutant form led
to the expression of comparable amounts of protein (Fig. 2B,
compare lanes 5 and 6 with lanes 7 and 8), only the injection of
wildtype mRNA resulted in an improvement of the phenotype
(Fig. 2, compare E and F). Quantification of these results (Fig. 2
G–J) confirmed the significantly lower rescue effect of mutant
Prpf4 compared to wildtype protein (Pearson x2 test, p = 0.00001),
suggesting that p.R192H results in a loss of function.
Figure 2. The p.R192H variant leads to a loss of function in vivo. (A) Expression of zebrafish Prpf4 carrying a mutation corresponding to
p.R192H does not have a dominant negative effect. Upper panel: Western blot detection of endogenous Prpf4 and exogenous HA-tagged Prpf4 in
embryos injected with RNAs indicated above. Lower panel: No defects in embryonic development were observed upon overexpression of wildtype or
p.R192H Prpf4. (B) Western blot showing Prpf4 protein levels in zebrafish injected with the indicated combinations of prpf4 morpholino (MO) and
RNA. (C–F) The p.R192H mutant fails to rescue a lethal prpf4 deficiency. Representative selections of 3 days post fertilization (dpf) larvae from
embryos injected with the indicated combinations of prpf4 morpholino (MO) and RNA. (G–J) Quantification of normal, deformed and dead animals
from four independent rescue experiments. The rescue effect (H vs. I) and the loss of function effect of the p.R192H mutation (I vs. J) were highly
significant (Pearson x2 test; n is the total number of injected animals). Please note that the control experiments (uninjected, MO and MO + wt RNA),
but not the characterization of p.R192H, were previously published as part of a larger knockdown study [22]. As the characterization of p.R192H has
been performed in the context of this study, we reproduce here the control data for clarity (with permission from Oxford University Press).
doi:10.1371/journal.pone.0111754.g002
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The p.R192H variant disrupts binding of PRPF4 to PRPF3
Phylogenetic alignment of the amino acid sequence of PRPF4
homologs revealed that arginine 192 of human PRPF4 is highly
conserved in evolution (Fig. 3A) and locates in a 34 amino acids
stretch essential for Prp4 function in yeast [26]. Since this basic
region contains a putative nuclear localization signal [27], it was
first tested whether p.R192H interferes with nuclear import and/
or subnuclear localization of PRPF4. The localization of human,
HA-tagged wildtype and p.R192H PRPF4 was analyzed in
transfected HeLa cells by indirect immunofluorescence. Both
proteins were found in the nucleus in a speckled pattern that is
characteristic for splicing factors and co-localized with the U5
snRNP associated splicing factor EFTUD2 (Fig. 3B–I). These
results indicate that the missense mutation p.R192H does not
affect the sub-cellular localization of PRPF4.
PRPF4 is a constituent of the U4/U6 di-snRNP and as such
becomes also integrated into the U4/U6.U5 tri-snRNP. In the
context of these snRNPs, PRPF4 directly interacts with PRPF3
(the product of the RP disease gene PRPF3), and the cyclophilin
PPIH [28,29]. To analyze whether p.R192H interferes with these
interactions, we generated [35S]-labeled, HA-tagged wildtype and
mutant PRPF4 by translation in rabbit reticulocyte lysates in vitro,
along with their potential interacting proteins. The proteins of
interest were then immunoprecipitated by anti-PRPF3 antibodies
and detected by autoradiography. As shown in Figure 3 J, anti-
PRPF3 antibodies efficiently co-precipitated wildtype PRPF4 but
not the p.R192H mutant (upper panel, compare lanes 3 and 4).
The interaction of PRPF4 with PPIH was not affected, suggesting
that PRPF4 p.R192H is not globally misfolded (Fig. 3J, lower
panel). Thus, the p.R192H amino acid exchange results in a
specific disruption of the binding of PRPF4 to PRPF3.
The p.R192H variant leads to a snRNP integration defect
of PRPF4
The data presented above pointed to a crucial function of the
residue 192 in the interaction of PRPF4 with PRPF3. The
missense mutation identified may disrupt this interaction by local
unfolding, or by preventing a defined interaction of arginine 192
with the corresponding interaction surface in PRPF3. To
distinguish between both possibilities and to assess the importance
of the physicochemical properties of this residue, we produced a
series of mutants where arginine 192 was replaced with lysine,
tryptophan or glutamate. These mutants were co-translated with
PRPF3 and assayed for binding by co-immunoprecipitation with a
PRPF3 antibody. Although the p.R192H mutant showed the
strongest effect, a decrease in PRPF3 binding was also observed for
all other variants tested (Fig. 4A). These data suggest that the
Figure 3. Characterization of the PRPF4 missense variant p.R192H identified in an RP patient. (A) Domain organization of PRPF4 (upper
panel). The p.R192H amino acid exchange is located between the splicing factor motif (SFM) and the WD40 repeat domain (WD). Amino acid
sequence alignment revealed a strong conservation of the affected arginine residue across species (lower panel). Identical residues are shown in red;
similarity greater than 70% (BLOSUM62) is indicated by a grey box. See table S1 for sequence accession numbers. (B–I) The subcellular localization of
PRPF4 is not affected by the p.R192H mutant. Wildtype (B–E) and the p.R192H form of PRPF4 (F–I) were detected in the nuclei of transfected HeLa
cells. Both proteins co-localized with EFTUD2 protein in a speckled pattern typical for splicing factors (B, F). Nuclei were control-stained with DAPI (E,
I). The scale bar in K is 20 mm and accounts for all images. (J) The p.R192H missense mutant impairs binding to PRPF3. Immunoprecipitation analysis
of in vitro translated [35S]-labeled PRPF4-PRPF3 complex (upper panel) using an anti-PRPF3 antibody revealed a significant reduction of co-
precipitated p.R192H-PRPF4 (compare lanes 3 and 4). The interaction of PRPF4 to PPIH in contrast, was not affected (compare lanes 9 and 10). Lanes
1, 2, 7 and 8 show 10% of the inputs, lanes 5, 6, 11 and 12 are mock immunoprecipitations.
doi:10.1371/journal.pone.0111754.g003
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arginine at position 192 engages in a specific contact with the
PRPF3 binding interface that is prevented in the p.R192H variant.
Mutational studies in yeast have suggested that Prp4 is
integrated into the U4/U6 snRNP via its binding to Prp3 [27].
It was hence a possibility that the p.R192H mutant of PRPF4
would not only disrupt the interaction with PRPF3 but also
interfere with its integration into spliceosomal complexes. Two
independent experiments were performed to test this possibility. In
a first approach, HEK293 cells were transfected with HA-tagged
versions of either wildtype or p.R192H PRPF4. Cellular lysates
were then immunoprecipitated with antibodies directed against
either PRPF31 (a U4/U6-snRNP specific component that does
not directly bind to PRPF4) or the Sm proteins common to
spliceosomal snRNPs (Fig. 4 B). A robust co-precipitation of
wildtype protein by both antibodies was observed, whereas the
p.R192H mutant PRPF4 was poorly co-precipitated (compare
lanes 3 with 4 and 5 with 6, respectively; see also lanes 1 and 2 for
inputs). In a second approach, wildtype and p.R192H mutant HA-
PRPF4 were immunopecipitated with anti-HA antibodies from
transfected HeLa cells and analyzed for co-precipitation of the tri-
snRNP snRNAs U4 and U6 as well as snRNA U1 as a control by
Northern blotting (Fig. 4 C). Although wildtype and mutant
proteins were precipitated with similar efficiency (lower panel), co-
precipitation of the snRNAs U4 and U6 was markedly reduced for
mutant PRPF4 (compare lanes 3 and 4). Thus, the p.R192H
PRPF4 variant is not stably incorporated into snRNPs.
We next considered the possibility that the uncovered
biochemical defect might also underlie the inability of p.R192H
mutant prpf4 mRNA to rescue the lethal Prpf4 knockdown in
zebrafish. This was addressed by analyzing the U snRNP
integration of wild type and mutant Prpf4 in zebrafish embryos.
Co-injections of morpholino against endogenous prpf4 together
with morpholino-insensitive in vitro transcripts encoding either
wildtype or p.R192H HA-Prpf4 were performed in an analogous
manner as described for the rescue experiments. At 10 hours post
fertilization (hpf), lysates of the embryos were prepared and
subjected to anti-HA immunoprecipitation. Co-precipitated
snRNAs were then analyzed by northern blotting using probes
specific for zebrafish U4 and U6 snRNAs. Similar levels of HA-
Prpf4 were recovered from animals injected with wildtype or
p.R192H RNA (Fig. 4D, lower panel), but the amount of
associated di-snRNP snRNAs was severely reduced for p.R192H
HA-Prpf4 (Fig. 4D, upper panel). Thus, the p.R192H mutation
interferes with the integration of PRPF4 into spliceosomal
complexes in vivo. Given the essential nature of this step in pre-
mRNA processing, this defect is a likely cause for the inability of
p.R192H RNA to rescue Prpf4 deficiency.
Discussion
In this study, we describe the identification of an isolated RP
patient that carries a heterozygous missense variant (p.R192H) in
the gene encoding the tri-snRNP splicing factor PRPF4. We show
that this variant disrupts the binding of PRPF4 to its interactor
PRPF3 in vitro. This leads to an impaired integration into
spliceosomal particles and a loss of physiological function in vivo.
PRPF4 has been shown previously to form a very stable ternary
complex with PRPF3 and the peptidyl-prolyl isomerase PPIH.
Within this ternary complex, PRPF4 acts as a bridging factor by
contacting PPIH via its N-terminal part and PRPF3 via its central
and C-terminal part [28,29]. Consistent with this mapping is our
observation that the p.R192H mutation affected PRPF3 binding
but not the association with PPIH. This mode of binding suggests
that p.R192H not only causes a defective integration of PRPF4
into the tri-snRNP, but that it might also lead to the concomitant
loss of PPIH, a protein necessary for efficient splicing [30].
Remarkably, a similar mechanism has been proposed for an RP-
mutant form of PRPF31 that is thought to sequester its interactor
PRPF6 out of the tri-snRNP [31], and an altered composition of
the tri-snRNP has also been described for RP-causing missense
mutations in PRPF8 [21].
Figure 4. The arginine residue at position 192 is essential for
integration of PRPF4 into snRNPs. (A) A series of mutants at
position 192 was analyzed for binding to PRPF3. Neither lysine
(positively charged) nor tryptophan (aromatic) nor glutamate (nega-
tively charged) were tolerated at this position. (B) Reduced co-
precipitation of p.R192H PRPF4 with snRNPs. HEK293 cells were
transfected with wildtype and mutant HA-PRPF4 and lysates were
immunoprecipitated using an anti-PRPF31 antibody (lanes 3 and 4),
anti-Sm-antibody Y12 (lanes 5 and 6) or mock precipitated (lanes 7 and
8). Lanes 1 and 2 show 10% of the input used for the immunoprecip-
itations. (C) PRPF4 p.R192H fails to associate with U4 and U6 snRNA.
HEK293 cells were transfected with HA-tagged PRPF4 in either wildtype
or p.R192H mutant form. Anti-HA immunoprecipitation was controlled
by Western blot (lower panel) and co-precipitated di-snRNP RNAs U4
and U6 were analyzed by Northern blotting (upper panel). U1 snRNA
served as a specificity control. (D) snRNA co-immunoprecipitation
experiments using zebrafish embryo lysates. Embryos were co-injected
with 50 pg wildtype or p.R192H HA-prpf4 mRNA and 0.5 ng prpf4-MO
to facilitate snRNP integration of exogenous protein. At 10 hpf, extracts
were prepared and immunoprecipitations were analyzed as described
in (C).
doi:10.1371/journal.pone.0111754.g004
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Our biochemical data strongly indicate that the p.R192H
variant leads to the production of non-functional protein and thus
represents a functional null allele. However, patient RP-106 has
two daughters, one of which was found to have inherited the
c.575G.A variant (Fig. 1). Both daughters underwent detailed
ophthalmological investigation and did not show signs of retinal
degeneration. While the genetic study presented here thus does not
allow to conclude whether PRPF4 is causally linked to RP,
additional evidence indicates that this is indeed the case: Our data
obtained in zebrafish showed that the sub-lethal knockdown of
Prpf4 leads to a retina-specific phenotype similar to that of RP
[22]. The data presented here shows that wildtype Prpf4, but not a
variant corresponding to p.R192H can rescue such Prpf4
deficiency (Fig. 2). Further support for a link between PRPF4
deficiency and RP comes from a recent study where PRPF4
mutations were found to cause adRP in a Chinese cohort [10].
Also, a potentially pathogenic missense variant of PRPF4
(p.P187A) was reported in two German siblings with RP [32].
Although this latter study failed to demonstrate a clear association
between PRPF4 and RP in North American and European
populations [32], these data indicate that rare defects in PRPF4
might cause RP in a limited subset of patients.
The absence of RP symptoms in the daughter who carries the
p.R192H variant of PRPF4 might be due to incomplete
penetrance or largely variable disease expressivity, both being
phenomena frequently observed for RP-associated mutations in
splicing factors [33–35]. For the PRPF31-linked autosomal
dominant RP, this has been explained by a modifier gene that
modulates PRPF31 transcription. Low expression of the modifier
increases wild-type PRPF31 levels to an extent that are sufficient to
prevent the development of disease symptoms in heterozygous
mutation carriers [36]. It has been proposed that the vulnerability
of retinal cells to splicing factor defects arises from an unmet
requirement for the production of sufficient amounts of mature
retinal mRNAs [20]. Thus, defects in different splicing factors
might act together to decrease the level of functional tri-snRNPs
below the threshold required in retinal cells. This does not
necessarily require a complete loss of the mutant protein from the
tri-snRNP, as demonstrated by an RP-causing missense mutation
in SNRNP200 which still allows integration of the mutant protein
into the tri-snRNP but causes a decrease in splicing efficiency and
fidelity [37]. It is possible that a hypomorphic variant in another
splicing factor is present in the patient, but not in her daughter,
and leads to the manifestation of RP. Moreover, it can not be
excluded that the RP of the patient is caused by biallelic mutations
in a recessive RP gene, and that p.R192H represents a rare non-
pathogenic variant.
Support for the notion that a decrease in overall tri-snRNP
activity rather than individual splicing factor defects lead to
photoreceptor damage comes from a zebrafish mutant of the tri-
snRNP recycling factor SART3: Although SART3 is an assembly
factor that is not itself part of the tri-snRNP [38], its mutation
leads to the reduced expression of photoreceptor mRNAs [39].
Taken together, our data are consistent with a model in which rare
mutations of tri-snRNP splicing factors act together to decrease the
level of functional tri-snRNPs below the threshold required in
retinal cells.
Materials and Methods
Plasmids and antibodies
Zebrafish prpf4 was amplified from 14 hpf embryonic oligo-dT
cDNA using gene-specific primers (see table S1 for sequences).
Human PRPF4 was amplified using the ‘‘Marathon human fetal
brain’’ cDNA library (Clontech) as a template and gene-specific
primers. cDNAs were inserted into a modified version of the
pcDNA3 vector that adds an N-terminal hemagglutinin- (HA-) tag
for the transfection of HeLa cells, into the pET21a, pET28a and
the pGEX-6P1 vector for in vitro translation and the production
of recombinant proteins and into an HA-tagged version of the
pCS2+ vector for in vitro transcription. To generate the
morpholino-insensitive prpf4, synonymous mutations were intro-
duced in the ATG region by site directed mutagenesis, resulting in
6 mismatches to the antisense morpholino sequence (see table S1
for sequences of mutagenic primers). The same approach was
applied to introduce the p.R177H mutation that corresponds to
the human p.R192H exchange. Antibodies against PRPF3,
PRPF4 and PRPF31 were described previously [22]. Antibodies
against EFTUD2 were a gift from R. Lu¨hrmann. The anti-HA
antibody (MMS-101R) was purchased from HiSS Diagnostics.
Microinjection and Western blot analysis of zebrafish
embryos
Microinjection of zebrafish embryos and Western blot analysis
of embryo lysates was performed as described previously [22].
Briefly, one- or two-cell stage embryos were injected with a
morpholino oligo directed against the start codon region of prpf4
(prpf4-MO: TGGAGCTTCATCTTCATCTGACATC; Gene
Tools, LLC). Lysates for Western blots were prepared by
homogenization of single larvae in 20 ml of a 1:1 mixture of
Laemmli sample buffer and buffer B (100 mM NaH2PO4, 10 mM
Tris pH 8.0, 8 M Urea).
Rescue experiments
Single clutches of embryos were divided into four groups that (1)
were left uninjected, (2) were injected with a lethal dose of prpf4-
MO (2 mg/ml), (3) were co-injected with prpf4-MO and wildtype
prpf4 mRNA or (4) were co-injected with prpf4-MO and
p.R192H mutant prpf4 mRNA. The co-injected mRNAs were
transcribed in vitro, capped and purified as described previously
[22]. Successful injection (knockdown of endogenous Prpf4 and
expression of exogenous HA-Prpf4) was monitored by Western
blotting at 12 hpf. After 4 dpf, larvae were scored as described [22]
as either lethal, severely deformed or slightly deformed/not
affected. At least three independent experiments were performed
for each analysis.
Immunocytochemistry
HeLa cells were grown on coverslips in DMEM (PAA)
containing 10% fetal calf serum (PAA) at 37uC and 5% CO2.
HA-PRPF4 inserted into the pcDNA3 vector was transfected using
Nanofectin (PAA) and two days after transfection cells were fixed
and immunocytochemistry was performed as described previously
[40].
In vitro translation, co-immunoprecipitations and
Northern blotting
Proteins were translated from pET21a and pET28a vectors
using the T7 TNT coupled transcription and translation kit
(Promega) in the presence of [35S]-L-methionine.
Extracts form HEK293 cells were obtained by sonication in
IPP300 (20 mM Tris pH 7.0, 300 mM NaCl, 0.05% NP40)
containing 1.5 mM MgCl2, 0.5 mM DTT and protease inhibitors.
Zebrafish embryo lysates were prepared from ,100 embryos
(10hpf) by sonication in 200 ml of IPP300 containing 0.5% NP40.
Crude lysates were extracted using 100 ml N-heptane and
centrifuged at 16.000 g and 4uC for 30 minutes.
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For immunoprecipitations, antibodies were coupled to either
protein A- or protein G-Sepharose and incubated with translated
proteins/cellular extract in IPP300. After excessive washing with
IPP300, bound proteins were eluted using Laemmli sample buffer
and analyzed by Western blotting or autoradiography.
For Northern blot analyses, PK-buffer (2x: 200 mM Tris-HCl
pH 7.5, 25 mM EDTA, 300 mM NaCl, 2% SDS) and phenol
were added to the immunoprecipitates. After phase separation, the
RNA was ethanol-precipitated, subjected to PAGE (10%, 8 M
Urea) and electroblotted onto Hybond N+ Nylon membrane (GE
Healthcare). Hybridization of [32P]-labeled oligonucleotides spe-
cific for U1, U4 and U6 snRNAs (see table S1 for sequences) was
carried out at 42uC in RapidHyb solution (GE Healthcare).
Patient screening and analysis
Samples were obtained with written informed consent. Clinical
investigations were conducted according to the Declaration of
Helsinki, and the study was approved by the institutional review
board of the Ethics Committee of the University Hospital of
Cologne. 85 patients with sporadic or autosomal dominant RP
were screened for mutations in the PRPF4 gene. All 14 coding
exons were PCR-amplified and the products were subjected to
SSCP (single strand conformation polymorphism) analysis. Prod-
ucts with band shifts were directly sequenced. All 85 patients with
no previously identified RP-mutations and 100 healthy control
individuals were genotyped for the presence of p.R192H by direct
sequencing.
Supporting Information
Table S1 Oligonucleotide sequences and accession
numbers used.
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